Tandem Diabetes Care Stock Forecast, Price & News

Tandem Diabetes Care (NASDAQ:TNDM) Frequently Asked Questions

Is Tandem Diabetes Care a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last year. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Tandem Diabetes Care stock.
View analyst ratings for Tandem Diabetes Care or view top-rated stocks.

What stocks does MarketBeat like better than Tandem Diabetes Care?

Wall Street analysts have given Tandem Diabetes Care a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Tandem Diabetes Care wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Tandem Diabetes Care?

Tandem Diabetes Care saw a increase in short interest during the month of September. As of September 30th, there was short interest totaling 4,550,000 shares, an increase of 23.0% from the September 15th total of 3,700,000 shares. Based on an average trading volume of 733,500 shares, the days-to-cover ratio is presently 6.2 days. Currently, 7.4% of the shares of the company are short sold.
View Tandem Diabetes Care's Short Interest.

When is Tandem Diabetes Care's next earnings date?

Tandem Diabetes Care is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for Tandem Diabetes Care.

How can I listen to Tandem Diabetes Care's earnings call?

Tandem Diabetes Care will be holding an earnings conference call on Wednesday, November 3rd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Tandem Diabetes Care's earnings last quarter?

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) released its quarterly earnings data on Wednesday, August, 4th. The medical device company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.14. The medical device company earned $172.14 million during the quarter, compared to analysts' expectations of $143.36 million. Tandem Diabetes Care had a net margin of 1.08% and a trailing twelve-month return on equity of 3.68%. The business's quarterly revenue was up 57.6% on a year-over-year basis. During the same period last year, the business earned ($0.45) EPS.
View Tandem Diabetes Care's earnings history.

How has Tandem Diabetes Care's stock been impacted by Coronavirus (COVID-19)?

Tandem Diabetes Care's stock was trading at $66.33 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TNDM shares have increased by 92.0% and is now trading at $127.37.
View which stocks have been most impacted by COVID-19.

When did Tandem Diabetes Care's stock split? How did Tandem Diabetes Care's stock split work?

Tandem Diabetes Care's stock reverse split on the morning of Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 9th 2017. An investor that had 100 shares of Tandem Diabetes Care stock prior to the reverse split would have 10 shares after the split.

What guidance has Tandem Diabetes Care issued on next quarter's earnings?

Tandem Diabetes Care updated its FY 2021 earnings guidance on Wednesday, September, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $670 million-$685 million, compared to the consensus revenue estimate of $637.16 million.

What price target have analysts set for TNDM?

8 brokers have issued 12-month price objectives for Tandem Diabetes Care's shares. Their forecasts range from $90.00 to $153.00. On average, they expect Tandem Diabetes Care's share price to reach $130.13 in the next twelve months. This suggests a possible upside of 2.2% from the stock's current price.
View analysts' price targets for Tandem Diabetes Care or view top-rated stocks among Wall Street analysts.

Who are Tandem Diabetes Care's key executives?

Tandem Diabetes Care's management team includes the following people:

• John F. Sheridan, President, Chief Executive Officer & Director
• James Leal, Senior Vice President-Operations
• Leigh A. Vosseller, CFO, Treasurer, Principal Accounting Officer & EVP
• Manuel Jaime, Senior Vice President-Technology & Digital Health
• Michael Michaud, Vice President-Research & Development

What is John Sheridan's approval rating as Tandem Diabetes Care's CEO?

11 employees have rated Tandem Diabetes Care CEO John Sheridan on Glassdoor.com. John Sheridan has an approval rating of 88% among Tandem Diabetes Care's employees.

Who are some of Tandem Diabetes Care's key competitors?

Some companies that are related to Tandem Diabetes Care include Fresenius SE & Co. KGaA (FSNUY), Insulet (PODD), Teleflex (TFX), Abiomed (ABMD), NovoCure (NVCR), Penumbra (PEN), Hill-Rom (HRC), Globus Medical (GMED), ShockWave Medical (SWAV), Inspire Medical Systems (INSP), Integra LifeSciences (IART), ICU Medical (ICUI), Inari Medical (NARI), Nevro (NVRO) and Merit Medical Systems (MMSI).
View all of TNDM's competitors.

What other stocks do shareholders of Tandem Diabetes Care own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tandem Diabetes Care investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Micron Technology (MU), DexCom (DXCM), Netflix (NFLX), Square (SQ), Roku (ROKU), Lululemon Athletica (LULU) and PayPal (PYPL).

What is Tandem Diabetes Care's stock symbol?

Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM."

Who are Tandem Diabetes Care's major shareholders?

Tandem Diabetes Care's stock is owned by many different retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (0.55%), Redwood Investments LLC (0.25%), Frontier Capital Management Co. LLC (0.11%), Assenagon Asset Management S.A. (0.07%), Oregon Public Employees Retirement Fund (0.03%) and Louisiana State Employees Retirement System (0.03%). Company insiders that own Tandem Diabetes Care stock include Brian B Hansen, Christopher J Twomey, David B Berger, Dick Allen, James Leal, John F Sheridan, Kim D Blickenstaff, Leigh Vosseller, Mark Reinstra, Rebecca B Robertson and Susan Morrison.
View institutional ownership trends for Tandem Diabetes Care.

Which major investors are selling Tandem Diabetes Care stock?

TNDM stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Frontier Capital Management Co. LLC, WealthTrust Axiom LLC, Level Four Financial LLC, and IFP Advisors Inc. Company insiders that have sold Tandem Diabetes Care company stock in the last year include Brian B Hansen, Christopher J Twomey, David B Berger, James Leal, Kim D Blickenstaff, Leigh Vosseller, Mark Reinstra, Rebecca B Robertson, and Susan Morrison.
View insider buying and selling activity for Tandem Diabetes Care or view top insider-selling stocks.

Which major investors are buying Tandem Diabetes Care stock?

TNDM stock was acquired by a variety of institutional investors in the last quarter, including Redwood Investments LLC, Oregon Public Employees Retirement Fund, Louisiana State Employees Retirement System, Tributary Capital Management LLC, New Mexico Educational Retirement Board, State of Alaska Department of Revenue, Pacer Advisors Inc., and Axiom Investment Management LLC.
View insider buying and selling activity for Tandem Diabetes Care or or view top insider-buying stocks.

How do I buy shares of Tandem Diabetes Care?

Shares of TNDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tandem Diabetes Care's stock price today?

One share of TNDM stock can currently be purchased for approximately $127.37.

How much money does Tandem Diabetes Care make?

Tandem Diabetes Care has a market capitalization of $8.03 billion and generates $498.83 million in revenue each year. The medical device company earns $-34.38 million in net income (profit) each year or ($0.39) on an earnings per share basis.

How many employees does Tandem Diabetes Care have?

Tandem Diabetes Care employs 1,500 workers across the globe.

When was Tandem Diabetes Care founded?

Tandem Diabetes Care was founded in 2006.

What is Tandem Diabetes Care's official website?

The official website for Tandem Diabetes Care is www.tandemdiabetes.com.

Where are Tandem Diabetes Care's headquarters?

Tandem Diabetes Care is headquartered at 11075 ROSELLE STREET, San Diego CA, 92121.

How can I contact Tandem Diabetes Care?

Tandem Diabetes Care's mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The medical device company can be reached via phone at (858) 366-6900 or via email at [email protected].